Alternative treatments for melanoma: targeting BCL-2 family members to de-bulk and kill cancer stem cells
For the first time new treatments in melanoma have produced significant responses in advanced diseases, but 30–90% of melanoma patients do not respond or eventually relapse after the initial response to the current treatments. The resistance of these melanomas is likely due to tumor heterogeneity, w...
| Main Authors: | , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537369/ |